Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden;
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California.
J Nucl Med. 2023 Oct;64(10):1632-1637. doi: 10.2967/jnumed.123.265523. Epub 2023 Jul 27.
In radiopharmaceutical therapy, intratumoral uptake of radioactivity usually leads to heterogeneous absorbed dose distribution. The likelihood of treatment success can be estimated with the tumor control probability (TCP), which requires accurate dosimetry, estimating the absorbed dose rate per unit activity to individual tumor cells. Xenograft cryosections of the prostate cancer cell line LNCaP treated with [Lu]Lu-PSMA-617 were evaluated with digital autoradiography and stained with hematoxylin and eosin. The digital autoradiography images were used to define the source in a Monte Carlo simulation of the absorbed dose, and the stained sections were used to detect the position of cell nuclei to relate the intratumoral absorbed dose heterogeneity to the cell density. Simulations were performed for Ac, Lu, and Y. TCP was calculated to estimate the mean necessary injected activity for a high TCP. A hypothetical case of activity mainly taken up on the tumor borders was generated and used to simulate the absorbed dose. The absorbed dose per decay to tumor cells was calculated from the staining and simulation results to avoid underestimating the tumor response from low absorbed doses in tumor regions with low cell density. The mean of necessary injected activity to reach a 90% TCP for Ac, Lu, and Y was found to be 18.3 kBq (range, 18-22 kBq), 24.3 MBq (range, 20-29 MBq), and 5.6 MBq (range, 5-6 MBq), respectively. To account for the heterogeneous absorbed dose generated from nonuniform intratumoral activity uptake, dosimetry models can estimate the mean necessary activity to reach a sufficient TCP for treatment response. This approach is necessary to accurately evaluate the efficacy of suggested radiopharmaceuticals for therapy.
在放射性药物治疗中,放射性活度在肿瘤内的摄取通常会导致不均匀的吸收剂量分布。治疗成功的可能性可以用肿瘤控制概率(TCP)来估计,这需要准确的剂量学,估计单位活性的吸收剂量率到单个肿瘤细胞。用[Lu]Lu-PSMA-617 处理的前列腺癌细胞系 LNCaP 的异种移植冷冻切片用数字放射自显影和苏木精-伊红染色进行评估。数字放射自显影图像用于在吸收剂量的蒙特卡罗模拟中定义源,并用染色切片检测细胞核的位置,将肿瘤内吸收剂量的异质性与细胞密度联系起来。对 Ac、Lu 和 Y 进行了模拟。计算 TCP 以估计高 TCP 所需的平均注入活动。生成了一个主要在肿瘤边界摄取的活动的假设情况,并用于模拟吸收剂量。从染色和模拟结果计算每个衰变到肿瘤细胞的吸收剂量,以避免因肿瘤区域细胞密度低而导致吸收剂量低而低估肿瘤反应。发现达到 90%TCP 所需的 Ac、Lu 和 Y 的平均注入活性分别为 18.3 kBq(范围,18-22 kBq)、24.3 MBq(范围,20-29 MBq)和 5.6 MBq(范围,5-6 MBq)。为了考虑到不均匀肿瘤内活性摄取产生的不均匀吸收剂量,剂量学模型可以估计达到足够 TCP 以获得治疗反应的平均所需活性。这种方法对于准确评估建议的放射性药物治疗的疗效是必要的。